PureTech Health PLC (GB:PRTC)
LSE:PRTC
Want to see GB:PRTC full AI Analyst Report?
Top Page
PureTech Health
(LSE:PRTC)
Select Model
Select Model
Rating:53Neutral
Price Target:
128.00 p
▼(-5.04% Downside)
Action:Reiterated
Date:05/06/26
The score is held back primarily by weak financial performance (ongoing losses, negative free cash flow, and limited revenue scale), partially offset by a relatively strong balance sheet. Earnings-call updates improve the outlook via clinical/portfolio progress, better operating loss, and stated runway, but funding/execution risk remains material. Technicals are broadly neutral and valuation is constrained by negative earnings and no dividend support.
Positive Factors
Hub-and-spoke monetization model
Public-listing progress at Seaport and an increased stake validate PureTech’s venture‑builder model and demonstrated ability to scale and monetize founded entities. This structural capability to create sellable or investable businesses underpins repeatable, non‑dilutive value creation over the medium term.
Negative Factors
Persistent negative cash flow
Sustained negative operating and free cash flow forces reliance on balance‑sheet resources or external financing for ongoing R&D and trial starts. Over multiple quarters this erodes equity headroom and increases execution risk for late‑stage programs if capital markets or monetization windows tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Hub-and-spoke monetization model
Public-listing progress at Seaport and an increased stake validate PureTech’s venture‑builder model and demonstrated ability to scale and monetize founded entities. This structural capability to create sellable or investable businesses underpins repeatable, non‑dilutive value creation over the medium term.
Read all positive factors
PureTech Health (PRTC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£316.44M
Dividend YieldN/A
Average Volume (3M)444.90K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue Growth-5.89%
EPS Growth-310.69%
CountryUK
Employees80
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.46
Shares Outstanding243,418,180
10 Day Avg. Volume437,187
30 Day Avg. Volume444,904
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.30
Price to Sales (P/S)85.14
P/FCF Ratio-4.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£240.00Price Target Upside78.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.58
Revenue Forecast (FY)£10.30M
PureTech Health Business Overview & Revenue Model
Company Description
PureTech Health plc, a biopharmaceutical company established in Boston, Massachusetts, in 2015, functions as a clinical-stage firm primarily within the United States. It is dedicated to discovering, developing, and bringing to market medical treat...
How the Company Makes Money
PureTech Health primarily makes money through (1) value creation and monetization of its equity stakes in affiliated companies it has founded or backed (e.g., proceeds from public listings, sales of shares, or other liquidity events), and (2) paym...
PureTech Health Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 27, 2026
Earnings Call Sentiment Positive
The call presented meaningful operational and clinical progress — notably positive Phase Ib data for Gallop (LYT‑200), Celea Phase IIb success and Phase III readiness, Seaport IPO momentum, improved operating loss and a confirmed runway through end‑2028 — while also acknowledging near‑term financial headwinds including a year‑over‑year cash decline, a swing to net loss driven by the absence of a one‑time 2024 gain, modest revenue, and the need for substantial external capital to fund late‑stage programs. Management emphasized capital discipline, earlier capitalization of founded entities, and intention to return cash to shareholders, but execution of financings (Celea, Gallop) and sensitivity to early product sales (Cobenfy) remain material risks.Positive Updates
Positive Gallop (LYT-200) Phase Ib Results
Top-line Phase Ib data showed an excellent safety profile (no dose-limiting toxicities or myeloid suppression), dose-dependent efficacy and identification of 12 mg/kg as the dose for next study. PureTech will prioritize relapsed/refractory high-risk MDS, plans FDA engagement for a potentially registration-enabling trial, and intends to seek majority third-party capital to fund next-stage development.
Negative Updates
Year‑over‑Year Cash Decline
PureTech-level cash fell from $366.8M at end-2024 to $277.1M at end-2025, a decline of $89.7M (≈24.5%). Consolidated cash moved similarly (≈24.5% decline). Unaudited Q1 2026 cash was ~$248.1M (≈10.5% decrease from end-2025).
Read all updates
Q4-2025 Updates
Positive
Negative
Positive Gallop (LYT-200) Phase Ib Results
Top-line Phase Ib data showed an excellent safety profile (no dose-limiting toxicities or myeloid suppression), dose-dependent efficacy and identification of 12 mg/kg as the dose for next study. PureTech will prioritize relapsed/refractory high-risk MDS, plans FDA engagement for a potentially registration-enabling trial, and intends to seek majority third-party capital to fund next-stage development.
Read all positive updates
Company Guidance
Management reiterated conservative financial guidance and operational priorities: PureTech-level cash and cash equivalents were $277.1M at 31‑Dec‑2025 and $248.1M (unaudited) at 31‑Mar‑2026 (consolidated $277.3M and $248.2M), and the company expects operational runway at least through end‑2028 inclusive of planned participation in founded‑entity fundraises; 2025 consolidated revenue was $4.7M (vs $4.8M in 2024), operating loss $98.5M (vs $136.1M in 2024) and consolidated net loss $110.1M (2024 included a $151.8M one‑time gain), while PureTech has received ~$125M from prior royalty monetization, cites ~ $160M projected value of Cobenfy economics through 2033 (analyst consensus) and says it has generated over $1B from monetizations to date. On R&D and portfolio metrics, management expects to progress up to three concept‑stage programs and nominate up to two development candidates over the next three years, will target closing Celea financing to support the Phase III SURPASS‑IPF by early Q3‑2026 (with trial to begin close to close), and for Gallop selected a 12 mg/kg dose for LYT‑200 and will pursue a potentially registration‑enabling trial in relapsed/refractory high‑risk MDS (100% of MDS patients in the Phase Ib had prior HMA; historical response after HMA failure 0–5%; TIBSOVO addresses ~3–5% of patients).PureTech Health Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.76M | 4.32M | 750.00K | 2.09M | 9.98M |
| Gross Profit | 1.34M | 4.32M | -92.91M | -136.81M | -100.49M |
| EBITDA | -97.17M | 37.38M | -17.68M | -79.94M | -46.95M |
| Net Income | -112.04M | 53.51M | -65.70M | -50.35M | -60.56M |
Balance Sheet | |||||
| Total Assets | 534.90M | 602.63M | 693.97M | 702.65M | 946.01M |
| Cash, Cash Equivalents and Short-Term Investments | 279.00M | 367.31M | 327.14M | 350.10M | 465.71M |
| Total Debt | 19.76M | 159.14M | 25.34M | 46.87M | 52.75M |
| Total Liabilities | 229.12M | 194.70M | 235.74M | 155.06M | 361.86M |
| Stockholders Equity | 312.19M | 414.71M | 464.07M | 542.22M | 593.51M |
Cash Flow | |||||
| Free Cash Flow | -86.92M | -134.38M | -106.16M | -180.97M | -163.94M |
| Operating Cash Flow | -86.92M | -134.37M | -105.92M | -178.79M | -158.27M |
| Investing Cash Flow | 64.62M | 240.89M | 68.99M | -107.22M | 197.38M |
| Financing Cash Flow | -6.46M | -16.96M | 78.14M | -29.83M | 22.73M |
PureTech Health Technical Analysis
Positive
134.80
Price Trends
129.91
Positive
126.50
Positive
126.67
Positive
Market Momentum
0.01
Negative
53.24
Neutral
67.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRTC, the sentiment is Positive. The current price of 134.8 is above the 20-day moving average (MA) of 130.89, above the 50-day MA of 129.91, and above the 200-day MA of 126.67, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 53.24 is Neutral, neither overbought nor oversold. The STOCH value of 67.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:PRTC.
PureTech Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £316.44M | -0.38 | -31.83% | ― | -5.89% | -310.69% | |
53 Neutral | £215.34M | -39.06 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £344.28M | -8.36 | -2929.47% | ― | ― | ― | |
46 Neutral | £23.60M | 35.54 | -197.54% | ― | 3.31% | 21.91% | |
43 Neutral | £81.30M | -4.83 | -116.21% | ― | 81.46% | -15.88% | |
41 Neutral | £27.48M | -7.57 | -1397.43% | ― | ― | 36.67% |
* Healthcare Sector Average
GB:PRTC
PureTech Health
131.40
3.20
2.50%
GB:AVCT
Avacta Group plc
73.00
41.00
128.13%
GB:IMM
ImmuPharma
4.41
2.09
90.28%
GB:SCLP
Scancell Holdings
20.75
11.25
118.42%
GB:4BB
4basebio UK Societas
525.00
-460.00
-46.70%
GB:AREC
Arecor Therapeutics PLC
62.50
19.00
43.68%
PureTech Health Corporate Events
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
PureTech’s Founded Entity Seaport Therapeutics Prices Upsized $254.9 Million Nasdaq IPO
Positive
May 1, 2026
PureTech Health said its founded entity Seaport Therapeutics has priced an upsized Nasdaq initial public offering of 14.16 million shares at $18 each, implying expected gross proceeds of about $254.9 million before fees and expenses. Following the...
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresPrivate Placements and Financing
PureTech Health Sharpens Strategy as Portfolio Advances and Cash Runway Extends to 2028
Positive
Apr 29, 2026
PureTech Health reported annual results for 2025, highlighting a refined capital allocation strategy and progress across its portfolio of Founded Entities in respiratory, oncology and neuropsychiatric indications. The group ended 2025 with approxi...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
PureTech to Delist Nasdaq ADSs and Focus Trading on London Stock Exchange
Neutral
Apr 29, 2026
PureTech Health, a biotherapeutics company listed in both London and New York, is concentrating its trading on the London Stock Exchange after determining that most liquidity, investor activity and governance are already centred in the U.K. The mo...
Business Operations and StrategyExecutive/Board Changes
PureTech-Founded Seaport Therapeutics Adds Veteran Neuropsychiatry Dealmaker to Board
Positive
Apr 27, 2026
PureTech-founded Seaport Therapeutics, a clinical-stage company developing neuropsychiatric medicines using its proprietary Glyph platform, has appointed veteran biotech executive Dr. Sharon Mates to its board of directors. Mates brings extensive ...
Business Operations and StrategyProduct-Related Announcements
PureTech Unit Gallop Oncology Reports Strong Early Data for LYT-200 in High-Risk Blood Cancers
Positive
Apr 22, 2026
PureTech Health’s founded entity Gallop Oncology reported positive topline Phase 1b data for LYT-200, a first-in-class anti-galectin-9 antibody, in heavily pretreated patients with relapsed or refractory high-risk myelodysplastic syndrome an...
Business Operations and StrategyFinancial Disclosures
PureTech Health Sets Date for 2025 Annual Results and Investor Presentation
Neutral
Apr 13, 2026
PureTech Health plans to release its Annual Report and financial results for the year ended December 31, 2025, on April 29, 2026, and will host a presentation and conference call that day, with a webcast accessible via its investor relations websi...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
PureTech’s Founded Entity Seaport Therapeutics Files for U.S. IPO
Neutral
Apr 13, 2026
PureTech Health said that its Founded Entity, Seaport Therapeutics, Inc., has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock. Key parameters of the IPO, in...
Business Operations and StrategyProduct-Related Announcements
PureTech’s Celea Posts Positive Phase 2b IPF Data, Paving Way for Phase 3 Deupirfenidone Trial
Positive
Apr 2, 2026
PureTech Health, through its wholly owned Founded Entity Celea Therapeutics, is advancing deupirfenidone, a deuterated form of the approved IPF drug pirfenidone, as a next-generation antifibrotic therapy. The company’s model centers on spinn...
Business Operations and StrategyProduct-Related Announcements
PureTech Spinout Seaport Advances GlyphAgo After Strong Phase 1 Anxiety Data
Positive
Apr 2, 2026
PureTech’s founded entity Seaport Therapeutics reported positive proof-of-concept topline data from a Phase 1 trial of GlyphAgo, an oral prodrug of agomelatine being developed for generalized anxiety disorder. The program originated on PureT...
Regulatory Filings and Compliance
PureTech Health Updates Share Capital and Voting Rights for March 2026
Neutral
Apr 1, 2026
PureTech Health has reported its share capital and voting rights position as of 31 March 2026, confirming an issued share capital of 257,927,489 ordinary shares, of which 14,509,299 are held in treasury. This leaves a total of 243,418,190 voting r...
Business Operations and StrategyProduct-Related Announcements
PureTech-Backed Seaport Validates Oral Prodrug Platform With Human Data on Depression Candidate
Positive
Mar 25, 2026
PureTech Health’s founded entity Seaport Therapeutics has reported first-in-human clinical and preclinical data for GlyphAllo, an oral prodrug of allopregnanolone built on its proprietary Glyph platform for lymphatic drug delivery. The data,...
Business Operations and StrategyExecutive/Board Changes
PureTech Health Issues Shares to President as RSUs Vest Under Performance Plan
Neutral
Mar 13, 2026
PureTech Health has reported the vesting of restricted share units granted in May 2023 to President Eric Elenko under its Performance Share Plan, following the achievement of performance conditions measured over three years to the end of 2025. The...
Regulatory Filings and Compliance
PureTech updates total voting rights and share capital for February 2026
Neutral
Mar 2, 2026
PureTech Health has reported its capital structure as of 28 February 2026, with 257,927,489 issued ordinary shares of one pence each, of which 16,118,451 are held in treasury. This leaves a total of 241,809,038 voting rights, a key figure for inve...
Business Operations and Strategy
PureTech Health to Highlight Strategy at Leerink Global Healthcare Conference
Positive
Feb 25, 2026
PureTech Health said its chief executive, Robert Lyne, and president and co-founder, Eric Elenko, will take part in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11, 2026. The session, which will be webcast, gives t...
Business Operations and StrategyProduct-Related Announcements
PureTech’s Deupirfenidone Wins U.S. and EU Orphan Status for Idiopathic Pulmonary Fibrosis
Positive
Feb 19, 2026
PureTech Health’s Founded Entity Celea Therapeutics is developing deupirfenidone (LYT-100), a next-generation antifibrotic designed to improve efficacy and tolerability in idiopathic pulmonary fibrosis, a rare and fatal lung disease. The com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.